MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full

Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently...

Related Keywords

United States ,Matt Notarianni ,Josephh Capper ,Public Health Service ,Mimedx Group Inc ,Drug Administration ,Exchange Commission ,Nasdaq ,Not Related ,Currently Under ,Sales Growth ,High Teens ,Fourth Quarter Adjusted ,Medx Group ,United States Food ,Warning Letter ,Human Cell ,Tissue Based Product ,Executive Officer ,Private Securities Litigation Reform Act ,Nasdaq Mdxg ,Mimedx Group ,Nc ,